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ABSTRACT Langmuir isotherms and fluorescence and atomic force microscopy images of synthetic model lung surfactants
were used to determine the influence of palmitic acid and synthetic peptides based on the surfactant-specific proteins SP-B
and SP-C on the morphology and function of surfactant monolayers. Lung surfactant-specific protein SP-C and peptides
based on SP-C eliminate the loss to the subphase of unsaturated lipids necessary for good adsorption and respreading by
inducing a transition between monolayers and multilayers within the fluid phase domains of the monolayer. The morphology
and thickness of the multilayer phase depends on the lipid composition of the monolayer and the concentration of SP-C or
SP-C peptide. Lung surfactant protein SP-B and peptides based on SP-B induce a reversible folding transition at monolayer
collapse that allows all components of surfactant to be retained at the interface during respreading. Supplementing Survanta,
a clinically used replacement lung surfactant, with a peptide based on the first 25 amino acids of SP-B also induces a similar
folding transition at monolayer collapse. Palmitic acid makes the monolayer rigid at low surface tension and fluid at high
surface tension and modifies SP-C function. Identifying the function of lung surfactant proteins and lipids is essential to the
rational design of replacement surfactants for treatment of respiratory distress syndrome.
INTRODUCTION
Treating premature infants with respiratory distress syn-
drome with replacement surfactants derived from natural
and synthetic sources has significantly reduced neonatal
mortality (Robertson and Halliday, 1998). Native surfactant
is complex, and includes multiple lipid species and four
specific proteins (SP-A, -B, -C, and -D). In fact, the lipid
and protein composition of native surfactant is quite differ-
ent even between cows and pigs, the sources of most ani-
mal-based replacement surfactants (Bernhard et al., 2000).
The composition variations among different clinically used
replacement surfactants are even greater and depend both on
the nature of extraction from the animal sources and the
choice of “additives” (Bernhard et al., 2000). However, a
fairly limited number of components are generally agreed to
be essential to surfactant performance in vivo and simplify
the choices for model systems for study (Robertson and
Halliday, 1998; Goerke, 1998). These include saturated
dipalmitoylphosphatidylcholine (DPPC), unsaturated phos-
phatidylcholines and phosphatidylglycerols (PG) (Veldhui-
zen et al., 1998), and the two amphiphilic surfactant-specific
proteins, SP-B (Hawgood et al., 1998) and SP-C (Johans-
son, 1998). Palmitic acid (PA), while found at low concen-
trations in native surfactants (Veldhuizen et al., 1998), is a
common additive to replacements surfactants such as Sur-
vanta (Bernhard et al., 2000). However, the function of PA
in the monolayer in native or replacement surfactants is not
well understood.
Proper pulmonary function requires low surface tensions
during expiration to minimize the work of breathing
(Schu¨rch et al., 1976). This would seem to require that lung
surfactant form rigid monolayers capable of low surface
tension on compression. However, lung surfactant mono-
layers also must be fluid enough to spread rapidly during the
expansion of the interface that accompanies inspiration
(Bastacky et al., 1995). Although the individual components
of lung surfactant are either good at lowering surface ten-
sion (DPPC, especially when mixed with PA) or fluidizing
the monolayer (unsaturated PG and PC, proteins), no single
lipid or protein exhibits both properties.
DPPC forms a semi-crystalline monolayer capable of
surface tensions near zero when fully compressed. How-
ever, DPPC fails as a lung surfactant (Poulain and Clem-
ents, 1995; Robertson and Halliday, 1998) as it is slow to
adsorb from aqueous suspension and respreads slowly when
compression is relieved. This help explains the significant
fraction of unsaturated phospholipids and hydrophobic pro-
teins in native surfactant (Veldhuizen et al., 1998; Hawgood
et al., 1998; Johansson, 1998). Although unsaturated lipids
and proteins facilitate surfactant adsorption and spreading,
they collapse at relatively high surface tensions via the
ejection of material from the monolayer (Tchoreloff et al.,
1991; Lipp, 1997; Lipp et al., 1998; Schu¨rch et al., 1976;
Nag et al., 1998). The ejected material does not readily
reincorporate into the monolayer on expansion (Lipp et al.,
1998) (see Fig. 2).
The contradictory requirements of lung surfactant mono-
layers have led to the “squeeze-out” theory of lung surfac-
tant function: the unsaturated lipids and proteins in lung
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surfactant are selectively removed or “squeezed-out” from
the monolayer during compression, leading to a DPPC-
enriched monolayer capable of low surface tension. How-
ever, in vitro studies of captive (Schu¨rch et al., 1998;
Ingenito et al., 1999) and pulsating (Krueger and Gaver,
1999) air bubbles in contact with aqueous surfactant show
that the necessary mass transfer to the interface requires that
the surfactant remain within a few nanometers of the inter-
face. Hence, current thought is that the lipids and proteins
“squeezed-out” from the monolayer occupy a “surface as-
sociated reservoir” near the interface (Schu¨rch et al., 1998).
In vivo, electron microscopy has shown areas within alveoli
that have discontinuous multilayer patches along with con-
tinuous monolayers (Bastacky et al., 1995; Schu¨rch et al.,
1998; Tchoreloff et al., 1991).
Langmuir monolayers at the air-water interface provide
experimentally useful model systems for studies of lung
surfactants and other amphiphilic molecules. Care is neces-
sary to extrapolate Langmuir monolayer behavior to lung
surfactant behavior in vivo, but general correlations be-
tween in vitro and in vivo behavior are starting to emerge
(Bernhard et al., 2000; Cochrane and Revak, 1991; Goerke,
1998; Jobe, 1998; Lipp et al., 1996, 1998). The phase
behavior of surfactants in two dimensions is determined by
pressure-area isotherms. Additional information about the
morphology of the monolayer domains is accessible by
modern visualization techniques such as fluorescence and
atomic force microscopy. We present isotherms, fluores-
cence microscopy, and atomic force microscopy to show
that the lung surfactant-specific proteins SP-B and SP-C and
peptides based on these proteins interact with the various
lipid species to create localized monolayer-to-multilayer
transitions that provide low surface tensions on compression
and rapid and repeatable respreading on expansion. These
lipid- and protein-induced transitions are modified by
changes in the monolayer mechanical properties induced by
the addition of palmitic acid to DPPC/POPG (palmitoylo-
leoylphosphatidylglycerol) monolayers. The net result of
these interactions is that all of the lipid and protein compo-
nents of lung surfactant remain at the interface (or at least
within Schu¨rch’s “surface associated reservoir” (Schu¨rch et
al., 1998)) during the entire compression and expansion
cycle; removal of a significant fraction of the unsaturated
and protein components of the monolayer, that is, classical
“squeeze-out,” is not required for low surface tensions.
Identifying the roles of the individual lipid and protein
species in lung surfactants is essential to more rational
design of replacement lung surfactants for treatment of
respiratory distress syndrome.
MATERIALS AND METHODS
Protein synthesis
Surfactant protein B is a 78-residue, lipid-associating protein found in
mammalian lung surfactant (Hawgood et al., 1998). Each monomer has
disulfide links at the mid-sequence, N-terminal, and C-terminal sections,
suggesting the main chain may assume a hairpin-like format. The native
SP-B protein has a net positive charge of 8 (10 cationic and 2 anionic
residues), a large fraction of strongly hydrophobic residues, and has four
amphipathic helical segments with the helical axes oriented parallel to the
interface (Gordon et al., 1996, 2000). Preparations from native material are
generally homodimeric.
The full-length human 78-amino acid sequence of surfactant protein
(SP-B1–78) is shown below. In each sequence, the charged residues are
indicated with a “” or a “” sign:
1   25
NH2-FPIPLPYCWLCRALIKRIQAMIPKG
  50
ALRVAVAQVCRVVPLVAGGICQCLA
     78
ERYSVILLDTLLGRMLPQLVCRLVLRCS-COOH
(Full-length SP-B)
To simplify synthesis and to try to isolate the essential features of SP-B, a
peptide based on the N-terminus of SP-B known as SP-B1–25 was synthe-
sized (Bruni et al., 1991). SP-B1–25 is able to recreate many of the functions
of the full-length SP-B protein both in vivo and in vitro (Lipp et al., 1996,
1998; Longo et al., 1993). Both full-length SP-B and SP-B1–25 form
amphipathic -helices (Gordon et al., 1996, 2000) that help orient the
protein at the interface. The amino acid sequence of SP-B1–25 is as follows:
1   25
NH2-FPIPLPYCWLCRALIKRIQAMIPKG-COOH
SP-B1–25
SP-C is a 4.2-kDa, dipalmitoylated, 35-residue peptide, of which 23
residues are hydrophobic. SP-C has a transbilayer orientation similar to that
of integral membrane proteins and adopts an -helical conformation be-
tween residues 9 and 34 (Johansson, 1998):
  
NH2-LRIPCCPVNLKRLLVVVVV
VVLVVVVIVGALLMGL-COOH
(SP-C)
The N-terminal segment includes two palmitoylcysteinyls () and is
flexibly disordered in solution. The length of the -helix is 3.7 nm and
orients along the acyl chains of lipids in a monolayer or bilayer environ-
ment (Gericke et al., 1997; Johansson, 1998). The hydrophobic character of
SP-C and palmitoylation makes native SP-C very difficult to synthesize.
We synthesized an analog of SP-C, SP-Cff (based on work by Byk-Gulden
Pharmaceutical, Konstance, Germany) (Ikegami et al., 1998; Ikegami and
Jobe, 1998) in which the palmitoylated cysteines are replaced by phenyl-
alanine residues ():
  
NH2-LRIPFFPVNLKRLLVVVVV
VVLVVVVIVGALLMGL-COOH
(SP-Cff)
This mutant protein performs nearly identically to the native SP-C in
animal models (Davis et al., 1998; Ikegami et al., 1998; Ikegami and Jobe,
1998) and is significantly easier to synthesize. This mutant is similar to dog
SP-C, which has only a single palmitoylated cysteine, with the second
replaced by phenylalanine (Batenburg and Haagsman, 1998).
Peptide synthesis reagents including Fmoc amino acids and coupling
solvents were obtained from Applied Biosystems (Foster City, CA). All
organic solvents used for sample synthesis, purification and preparation
were HPLC grade or better from Aldrich Chemical Co. (Milwaukee, WI).
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The full-length and peptide versions of SP-B were synthesized by the
solid-phase method of Merrifield, with the use of a tert-butyloxycarbonyl
strategy or by Fmoc strategies (UCLA Peptide Synthesis Facility). The
crude peptides were purified by C4-column (Vydac, Hesperia, CA) re-
versed-phase high-performance liquid chromatography (HPLC) with a
mixture of water, acetonitrile, and 0.1% trifluoroacetic acid. Solvents from
HPLC and ion-pairing agents were removed from the purified peptides by
vacuum centrifugation, and the expected molecular mass of the peptide was
obtained by fast atom bombardment mass spectrometry or electrospray
mass spectroscopy (UCLA Center for Molecular and Medical Sciences
Mass Spectrometry). Quantitative amino acid composition for the peptide
was determined at the UCLA Protein Microsequencing Facility.
SP-Cff was synthesized on a 0.25 mmol scale using an Applied Bio-
systems 431A peptide synthesizer using FastMoc chemistry. The peptide
was synthesized using a prederivatized Fmoc-leu-PEG-PS resin (PerSep-
tive Biosystems, Farmington, MA) having a substitution of 0.18 mmol/g.
Residues Gly-33 to Gly-29 were single-coupled, while the remaining
sequence was double-coupled to the N-terminus. Cleavage and deprotec-
tion of the peptide-resin was carried out in a 10-ml TFA, 0.25-ml ethanedi-
thiol, 0.5-ml thioanisole, and 0.5-ml water mixture for 1.5 h. The reaction
mixture was then removed by vacuum filtration through a medium porosity
fritted glass funnel and the resin washed sequentially with 1 ml TFA, then
5 ml DCM, and finally with 5 ml of isopropanol/TFA (95:5, v/v) to ensure
separation of the peptide from the resin.
The crude peptide was purified by reverse-phase HPLC with a Vydac
C4 column (1 cm  20 cm; The Separations Group, Hesperia, CA) using
a water-acetonitrile/isopropanol (1:1, v/v) linear gradient with 0.1% TFA
as an ion-pairing agent. The molecular weight of the full length SP-Cff was
confirmed by MALDI-TOF mass spectrometry using a Voyager RP-RBT2
reflection time of flight mass spectrometer (PerSeptive Biosystems, Inc.,
Framingham, MA). -Cyano-4-hydroxycinnamic acid was used as a matrix
and bovine insulin was used as an internal calibration standard.
Preparation of model monolayers
Model monolayers were spread from organic solvents by mixing the
proteins or peptides with the appropriate amounts of saturated DPPC,
unsaturated POPG, and PA (all from Avanti Polar Lipids, Inc., Alabaster,
AL; 99% purity) in the weight ratios of 68:22:8 in 3:1 chloroform/methanol
(Fisher Spectranalyzed). This lipid mixture is a close functional mimic to
natural lung surfactants both in vitro and in vivo (Tanaka et al., 1986).
However, the composition of native surfactant varies significantly from
species to species, and the compositions of replacement surfactants vary
even more due to difficulties in extraction and in the number and type of
additives used, so there is no universally accepted surfactant composition
as yet (Bernhard et al., 2000; Mizuno et al., 1995). The fluorescent probe
1-palmitoyl, 6-(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl-)-PG (NBD-PG, Mo-
lecular Probes, Eugene, OR) was added at lipid mole ratios of 0.5 to 1%.
The fluorescent probe segregates to disordered or fluid phases, which then
appear bright in images; the probe is absent from the solid or liquid
condensed phases, which appear black or dark (Knobler and Desai, 1992).
Survanta was purchased from Ross Laboratories (Columbus, OH).
Survanta is natural bovine lung extract containing phospholipids, neutral
lipids, fatty acids, and the surfactant-associated proteins SP-B and SP-C, to
which DPPC, PA, and tripalmitin are added to standardize the composition.
The approximate composition is 25 mg/ml phospholipid (of which 50–
60% is DPPC), 0.5–1.75 mg/ml triglycerides, 1.5–3.5 mg/ml free fatty
acids. Survanta contains both native SP-B and SP-C, but in concentrations
less than that of native surfactant due to losses during the extraction
process. For these experiments, the lipids and proteins were diluted in 0.9%
sodium chloride solution at a total concentration of 2 mg/ml. For fluo-
rescence experiments, NBD-PG was added to the Survanta by suspending
the dye in the same sodium chloride solution, then adding a small percent-
age (0.5 wt %) to the Survanta solution by gentle swirling. Additional SP-B
peptide was added by the same procedure. The Survanta suspension was
spread at the interface by depositing small drops of the aqueous suspension
onto the subphase surface.
All other monolayers were spread from a 3:1 chloroform/methanol
spreading solution at typical concentrations of 0.5–1 mg/ml onto a 150 mM
NaCl, 5 mM CaCl, 0.2 mM NaHCO3, pH 6.9 subphase in a temperature-
controlled microfluorescence film balance (Lipp et al., 1997a; Lipp, 1997).
The trough is milled from a solid piece of Teflon with a working surface
area of 120 cm2 and a subphase volume of 150 ml. A single Teflon
barrier runs linearly along the top edge of the trough and is driven by a
motorized translation stage. The barrier is spring-loaded against the trough
and the ends of the barrier in contact with the well edges are beveled at an
angle of 10° to minimize leakage of surfactant. Temperature control of
the subphase is achieved through the use of nine thermoelectric cooling
elements. The trough can be operated over a temperature range of 10–
50°C. A simple feedback loop allows for measurement and control of the
subphase temperature. The surface pressure is measured by a Wilhelmy
plate-type transducer with a filter-paper plate (R&K, Wiesbaden, Germany).
For fluorescence imaging, a Nikon Optiphot with the stage removed is
positioned above the trough. A 40 power long-working-distance objec-
tive designed for use with fluorescence systems is used. The trough is
mounted on a motorized xyz translation stage: the z axis is used for
focusing and the x and y axes are used to scan over different regions. A
100-watt high-pressure mercury lamp was used for excitation. A dichroic
mirror/barrier filter assembly is used to direct the excitation light onto the
monolayer (with a normal angle of incidence) and to filter the emitted
fluorescence. The emitted fluorescence is collected by the objective and
detected via a Silicon Intensified Target (SIT) camera. Images are recorded
by a JVC super VHS VCR and digitized via a Scion frame grabber. The
resulting digitized images are processed and analyzed following a custom-
designed protocol (Lipp et al., 1997b).
The monolayers were examined over a range of temperatures between
30 and 37°C; for these lipid and protein mixtures there was no significant
difference in isotherms or morphology over this temperature range (Lipp et
al., 1997a; Takamoto, 1999). Due to the increased convection and leakage
around the barriers at the higher temperature, transfers for AFM were done
primarily at 30°C (Lee et al., 1998). All isotherms presented are typical;
each isotherm was repeated numerous times to ensure reproducibility.
Compressions were done quasi-statically: the typical time for a compres-
sion-expansion cycle was 1 h. No variations of the isotherms were found
for rates twice as fast or as slow.
Selected monolayers were transferred to mica substrates for AFM using
a custom-built monolayer transfer system (Lee et al., 1998). A modified
Nanoscope III FM (Digital Instruments, Santa Barbara, CA) was used for
imaging. A low-resolution fluorescence optical microscope was used to
position the AFM tip onto specific regions of the sample (Lee et al., 1998).
Once the desired regions were located, AFM imaging was done with a 150
m  150 m (J) scanner in contact mode. Silicon nitride tips with a
spring constant of 0.12 N/m were used. Exerting large forces on the sample
was a concern during imaging, so samples were checked often for defor-
mation. This was done by imaging for a few minutes on a smaller region
(20 m), then zooming out to check whether damage had been done to
the scanned region.
Monolayer mechanical properties were measured using a custom-built
monolayer viscometer based on a design by Brooks et al. (1999). A
dual-barrier custom-built trough was equipped with parallel hydrophilic
glass plates spaced 1.5 cm apart to create a 10-cm-long flow cell within the
trough. A small magnetic needle (1 cm long and 0.5 mm in diameter) in
a Teflon boat was floated on the air-water interface between the two glass
plates. A force was applied parallel to the long axis of the needle by a
magnetic field gradient created by a pair of Helmholtz coils located on
opposite sides of the trough. The magnitude of the magnetic field gradient,
and hence the force on the needle, is proportional to the current in the coils.
The needle position is followed with a video camera to determine the
velocity of the needle. The needle rapidly comes to a steady velocity for a
given force. The velocity is proportional to the viscosity of the monolayer;
high needle velocities imply low monolayer viscosity, low needle veloci-
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ties imply a higher monolayer viscosity. As the monolayer is certainly
non-Newtonian, we cannot report a single viscosity, but rather just com-
pare the terminal velocities at a given applied force. The velocity is
normalized with respect to the needle velocity of the clean subphase.
Temperature control was not available for this trough, so all measurements
were done at25°C. The needle sinks at sufficiently high surface pressure,
so measurements are limited to 50 mN/m.
RESULTS
Fig. 1 A shows typical cyclic isotherms (compression-ex-
pansion-compression) for the DPPC/POPG/PA, 68:22:8
(wt/wt/wt) model lipid mixture on a buffered saline sub-
phase (150 mM NaCl, 5 mM CaCl, 0.2 mM NaHCO3,
pH	 6.9) at 30°C without protein. The surface pressure, ,
is the difference between the bare water surface tension
(72 mN/m for saline at 30°C) and the measured surface
tension, :  	 72  . Hence, a high surface pressure
corresponds to a low surface tension. While the lipid mix-
ture achieves high surface pressures, the second compres-
sion is shifted to lower area per molecule due to the selec-
tive removal, or squeeze-out of the unsaturated POPG
(Lipp, 1997; Takamoto, 1999). By the second compression,
most of the POPG has been lost to the subphase irreversibly.
The collapse pressure of a monolayer is the highest surface
pressure or lowest surface tension attainable before the film
fails. High and reproducible collapse pressures are essential
to minimizing the work of breathing. However, for the
lipids alone, on repeated compression, the collapse pressure
steadily decreased.
Fig. 1 B shows the change in the isotherm on addition of
2 wt % SP-Cff peptide (Davis et al., 1998) to the DPPC/
POPG/PA, 68:22:8 (wt/wt/wt) lipid mixture at 30°C. For the
second and subsequent compressions, the peptide induces a
break in the isotherm at a surface pressure of 50 mN/m
and the offset in molecular area is reduced, especially at
high surface pressure. The protein helps retain the unsatur-
ated lipid components in the surface film. The maximum
surface pressure increases to 70 mN/m on the second and
subsequent compressions. For these lipid and protein mix-
tures there was no significant difference in isotherms or
morphology over the temperature range of 30–37°C. (Lipp
et al., 1997a; Takamoto, 1999).
Contact mode AFM images of the SP-Cff containing
monolayers show the change in morphology at surface
pressures above and below the break in the isotherm. Fig. 2
A shows coexisting solid (light gray) and fluid (dark gray)
phase domains in a DPPC/POPG/PA/SP-Cff, 68:22:8:2 (wt/
wt/wt/wt) monolayer transferred at a surface pressure of 45
mN/m at 30°C (Lee et al., 1998). The domain sizes and
shapes are consistent with fluorescence images at the air-
water interface before transfer (von Nahmen et al., 1997;
Takamoto, 1999). The solid phase is made up primarily of
DPPC and PA (Lipp, 1997), and the fluid phase is primarily
POPG and protein (Lipp et al., 1998; von Nahmen et al.,
1997). The height trace shows that the fluid phase is 1–2 nm
lower than the solid phase. This difference is due to the
combination of the greater thickness of the solid phase
monolayer relative to the fluid phase monolayer, and the
greater compressibility of the fluid phase (Marsh, 1990).
Fig. 2 B shows an AFM image of the same film trans-
ferred at a surface pressure of 55 mN/m and 30°C, above the
break in the isotherm. The fluid phase domains (light gray)
are 4 nm higher than the solid phase (dark gray). This shows
that the fluid phase has increased in thickness by 5–6 nm in
comparison to Fig. 2 A, which is roughly equal to a bilayer
of POPG (Marsh, 1990). The addition of SP-Cff to the lipid
mixture induced a two- to three-dimensional phase transi-
tion. Instead of being squeezed-out, the unsaturated lipid
remains at the interface, although in a multilayer, rather than
a monolayer, form. Without the protein, the fluid phase is
almost completely removed from the interface (Takamoto,
1999).
DPPC/POPC (palmitoyloleoylphosphatidylcholine),
DPPC/PA/POPC, DPPG (dipalmitoylphosphatidylglyc-
erol)/POPG (Takamoto, 1999), and DPPC/DPPG (von Nah-
men et al., 1997) lipid mixtures showed similar transitions
in the presence of native human recombinant SP-C (von
Nahmen et al., 1997) or SP-Cff (Takamoto, 1999). SP-C and
SP-Cff contain a hydrophobic -helix segment that is capa-
ble of spanning a lipid bilayer (Johansson, 1998). At 50
mN/m surface pressure, the orientation of SP-C likely
switches from parallel to perpendicular to the interface,
allowing SP-C to bridge the thickened fluid lipids (Gericke
et al., 1997; von Nahmen et al., 1997). The thicker fluid
phase allows the surface pressure to be distributed over a
wider cross section; hence, the absolute force on the fluid
domain is smaller than that required to squeeze the lipids
out of the interface. On expansion, these thickened patches
quickly reincorporate into the monolayer at surface pres-
sures below 45 mN/m.
Surprisingly, the fluid phase transition depends on the
properties of the solid phase. Fig. 1 C shows the isotherm of
a 3:1 DPPC/POPC lipid mixture with 2 wt % SP-Cff at
30°C. Instead of the small break in the isotherm at 50
mN/m (Fig. 1 B), there is a distinct plateau at a pressure of
40 mN/m, and another break in the isotherm at 55 mN/m
on the second compression. Fig. 2 C shows an AFM image
above the first plateau in the isotherm at 50 mN/m. With no
PA in the solid phase, the fluid phase forms multilayer steps
rather than uniformly thickening (Fig. 2 B). This is the same
behavior as observed earlier for 3:1 DPPC/DPPG mixtures
with human recombinant SP-C (von Nahmen et al., 1997);
hence it appears that the palmitoylated cysteines are not
essential for this transition (see sequence information in
Materials and Methods). When PA is added to DPPC mono-
layers, the molecular tilt decreases, increasing the thickness
of the monolayer; the molecular ordering becomes longer-
ranged, and the temperature range of the solid phase in-
creases (Lipp, 1997; Lee, Majewski, von Nahmen, Gopal,
Howes, Kjaer, Smith and Zasadzinski, submitted for publi-
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FIGURE 1 (A) Quasi-static cycling isotherms (compression–expansion–compression) for a DPPC/POPG/PA, 68:22:8 (wt/wt/wt) lipid mixture on a
buffered saline subphase (150 mM NaCl, 5 mM CaCl, 0.2 mM NaHCO3, pH 	 6.9) at 30°C. There were no significant variations in any of the isotherms
over the temperature range of 30–37°C. Without protein, the second compression shows a significant offset in area per molecule likely due to loss of the
unsaturated POPG to the subphase. Subsequent compressions show that the POPG is irreversibly lost and the maximum surface pressure steadily decreases.
Surface pressure (reduction in surface tension from the clean interface) is plotted versus the area per lipid molecule in A–C. (B) Cycling isotherms of the
same lipid mixture and subphase as (A), but with 2 wt % SP-Cff added at 30°C. The plateau in the isotherm at a surface pressure of 50 mN/m is obvious
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cation). These changes likely lead to changes in the me-
chanical properties of the monolayer. This may explain the
benefits obtained by supplementing bovine lung surfactant
extract with palmitic acid in the clinically used Survanta.
However, the PA fraction in native surfactants extracted by
lavage is typically lower and ranges from 0 to 3 wt %
(Batenburg and Haagsman, 1998), so the role of PA in
natural surfactants is less clear.
To measure monolayer mechanical properties, we have
designed and built a magnetic needle monolayer viscometer
(Brooks et al., 1999). The basic principle is that a small
magnet supported in a Teflon “boat” floating on the mono-
layer surface is subjected to a constant force using a con-
trolled magnetic field gradient in the plane of the monolayer
and oriented along the axis of the “boat.” Higher needle
velocities correspond to low monolayer viscosity and low
needle velocities with high viscosity for a given magnetic
force. The velocity is normalized to the speed of the needle
on a clean subphase. Fig. 3 shows the normalized needle
velocity for a given applied magnetic force for a monolayer
of 77 wt % DPPC and 23 wt % POPG with varied PA
fractions on a pure water subphase at 25°C. With no PA in
the monolayer, the needle velocity is constant for all surface
pressures and is nearly the same as for a clean interface with
no surfactant (normalized speed of 1). For 10 wt % PA, we
see a dramatic decrease in needle velocity at surface pres-
sures from 35 to 40 mN/m, which corresponds to a large
increase in viscosity. This PA-induced change in the mono-
layer rigidity at high surface pressure correlates with the
changes in monolayer morphologies between Fig. 2, B and
C. The optimal PA content suggested by Tanaka (Tanaka et
al., 1986) in developing Survanta is 10% by weight. At
this PA fraction, there is a high viscosity at high surface
pressure, but low viscosity at low surface pressure. This PA
fraction also corresponds to changes in the tendency of the
monolayer to fold rather than fracture at collapse (Taka-
moto, 1999). A high viscosity at high surface pressure
appears to be necessary for the morphological transitions
shown in Fig. 2, but a low viscosity at low surface pressures
may be necessary for good monolayer respreading. At 20 wt
% PA, the needle velocity begins to decrease on initial
compression; by a surface pressure of 20 mN/m, the film
is so rigid that the needle cannot move with the maximum
force we can apply.
The net result of adding 10 wt % PA to the monolayer
is that the surface pressure is higher for a given compression
with PA than without PA (See Fig. 1, B and C; compare
small break in the isotherm in 1 B with the distinct plateau
in 1 C), and the uniformly thickened fluid phase (Fig. 2 B)
likely reincorporates more efficiently into the monolayer on
expansion than does the step-wise thickened fluid phase
without PA (Fig. 2 C). This explains one of the benefits
derived from supplementing bovine lung surfactant extract
with PA in the production of Survanta. Hexadecanol can be
substituted for PA and produces similar effects on DPPC
packing in the solid phase, and on isotherms and monolayer
morphology (Takamoto, 1999). This helps explains the role
of hexadecanol in Exosurf, another clinically used replace-
ment surfactant (Poulain and Clements, 1995).
The consistent behavior of SP-C with the wide variety of
solid and fluid phase lipids suggests that a similar transition
should occur in the more chemically complex bovine lung
surfactant extract, Survanta. Fig. 1 D shows cyclic iso-
therms for Survanta at 37°C, which was deposited from the
aqueous suspension directly onto the subphase. The iso-
therm was similar to the model lipid/SPCff mixture shown
in Fig. 1 B. On the second and subsequent compressions, a
small break in the isotherm was present at 45–50 mN/m, just
as in the model mixture (Fig. 1 B). AFM images of films
transferred (Lee et al., 1998) at 45 mN/m (Fig. 2 D) and at
55 mN/m (Fig. 2 E) at 30°C showed the same transitions as
the model mixture. In Fig. 2 D, below the break in the
isotherm, the solid phase domains (light gray) are 1–2 nm
thicker than the fluid domains (dark gray), similar to Fig. 2
A. The small white spots are lipid aggregates trapped during
the transfer from the air-water interface to the substrate. Fig.
2 E shows the film transferred at 55 mN/m, above the break
in the isotherm. As in Fig. 2 B, the fluid phase domains are
uniformly thicker by 1–2 nm than the solid phase, indicating
that the native SP-C in Survanta induces a similar morpho-
logical change as SP-Cff or the human recombinant SP-C
(von Nahmen et al., 1997). The change in thickness is not as
great as in the model mixtures, and is not consistent with the
thickness of the typical bilayer thickness of 5 nm. This
may be due to the smaller SP-C fraction in Survanta than in
the model mixtures or in native surfactant (Walther et al.,
1998; Mizuno et al., 1995), the lack of palmitoylation in the
SP-Cff used in the model mixtures, or to difficulties in
on the first compression. The second and subsequent compressions show a small break in the isotherm at the same surface pressure as the original plateau
and the collapse pressure increases to 
70 mN/m. The offset in area per molecule is diminished, suggesting that less POPG is lost to the subphase. (C)
Cycling isotherms of 3:1 DPPC/POPC with 2 wt % SP-Cff at 30°C. Instead of the small break in the isotherm at 50 mN/m (B), there is a distinct plateau
at a pressure of 40 mN/m, and another break in the isotherm at 55 mN/m on the second and subsequent compressions. Without PA, the surface pressure
for a given compression is less than with PA (B). There is even less offset in area per lipid molecule between the first and second cycles in the presence
of PA (B). (D) Cycling isotherms of Survanta on the same subphase as (A, B) at 30°C. The first compression shows a very similar break in the isotherm
as in (B), which is retained on subsequent compressions. There appears to be almost no offset in area per molecule after the first compression. (E) Cycling
isotherms of Survanta with 5 wt % added SP-B1–25 peptide at collapse at 37°C. The isotherm is quite similar to that in D. The peptide partitions mainly
into the fluid phase domains and does not affect the solid phase domains to any great extent.
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FIGURE 2 (A) Contact mode AFM image of model lung surfactant monolayer (DPPC/POPG/PA/SP-Cff in weight ratio of 68:22:8:2) transferred from
the air-water interface at a surface pressure just below the break in the isotherm (45 mN/m, see Fig. 1 B) onto a mica substrate (Lee et al., 1998) at 30°C.
The height trace (white line in image) shows the solid phase domains (light gray) are 1–2 nm thicker than the fluid phase domains (dark gray). The solid
phase domains consist of all trans, extended chains (Lee et al., submitted for publication) and are expected to be thicker and less compressible than the
fluid phase domains, which consist of disordered chains (Marsh, 1990). The irregular shape and 5–10 micron size of the solid phase domains are the same
as observed at the air-water interface with fluorescence microscopy. (B) Contact mode AFM image of the same film (DPPC/POPG/PA/SP-Cff in weight
ratio of 68:22:8:2) transferred at a surface pressure of 55 mN/m at 30°C, which is above the break in the isotherm. Now, the fluid phase domains are light
gray, indicating that the fluid phase is thicker than the solid phase (dark gray). The height trace (white line in image) shows that the fluid phase is 4 nm
higher than the solid phase. This shows that the fluid phase has increased in thickness by 5–6 nm in comparison to Fig. 2 A. (C) AFM image of 3:1
DPPC/POPC, with 2 wt % SP-Cff transferred at a surface pressure above the first plateau in the isotherm at 50 mN/m and 30°C. When the solid phase
consists of only DPPC, the fluid phase forms multilayer steps rather than a uniformly thickened fluid phase (B). This stepped morphology is similar to that
observed in DPPC/DPPG films with palmitoylated human recombinant SP-C (von Nahmen et al., 1997). (D) AFM image of Survanta monolayer transferred
at a surface pressure of 45 mN/m at 30°C, just below the plateau in the isotherm. The fluid phase (dark gray) is 1–2 nm lower than the solid phase domains
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transfer for AFM of the more complex mixtures. Higher
SP-Cff fractions likely led to a proportionately greater
change in the fluid phase thickness in the model mixtures
(Takamoto, 1999). The uniform change in thickness of the
fluid phase domains is likely due to the PA added to
Survanta. SP-B can also lead to the formation of a mono-
layer to multilayer transition in the fluid phase lipids (Krol
et al., 2000; Lipp et al., 1998). Mixture of native SP-B and
SP-C with phosphatidylcholines show a similar thickening
transition by AFM (Grunder et al., 1999), although the
morphology of the multilayer patches is less well defined
and smaller with SP-B than with SP-C (Krol et al., 2000;
Lipp et al., 1998).
While SP-C is responsible for helping maintain the fluid
lipids in the vicinity of the air-water interface, the SP-B
protein modifies monolayer collapse, thereby ensuring re-
producibly low surface tensions (Lipp et al., 1998). Fig. 4 A
shows a fluorescence microscopy image of a 67:22:8:3
(wt/wt/wt/wt) DPPC/POPG/PA/full length SP-B1–78 with
0.5 mol % of the fluorescent probe NBD-PG at the collapse
pressure of 65 mN/m at 37°C. The monolayer undergoes a
three-dimensional buckling into the subphase (bright area
in center of image), but maintains the monolayer morphol-
ogy of solid phase domains (dark) in a continuous fluid
phase (bright) not only at the interface, but throughout the
folded region. There is no loss of material to the subphase
on collapse. The buckled areas reincorporate into the mono-
layer on expansion over a range of surface pressures from
the collapse pressure to 10 mN/m.
Fig. 4 B shows a fluorescence image of Survanta at its
collapse pressure at 37°C. The bright streak is a fracture in
the monolayer. These fractures are similar to those in pure
DPPC monolayers (Lipp, 1997) at collapse, and lead to
inefficient respreading. The monolayer exhibits the similar
bright-dark, solid-fluid coexistence as the model mixture,
although the domain sizes are smaller. It is estimated that
the amount of SP-B in Survanta is only0.1 wt % (Walther
et al., 1997; Taeusch et al., 1986), while the amount of SP-B
in native surfactant is closer to 1.5–2 wt % (Mizuno et al.,
1995). However, the exact amount of SP-B, SP-C, or lipid
in any native surfactant or surfactant extract has not been
accurately measured because reliable methods of harvesting
surfactant from the alveoli are not available (Mizuno et al.,
1995). When 5 wt % SP-B1–25 is added to the Survanta
suspension, collapse occurs via buckling (Fig. 4 C), just as
in the model mixture with protein (Fig. 4 A). The folded
regions of the monolayer have similar morphology, and
likely composition, to the rest of the monolayer. The folded
material rapidly reincorporates into the monolayer on ex-
pansion, again over a range of surface pressure from col-
lapse to 15 mN/m. Fig. 1 E shows the cycling isotherms
of Survanta with 5 wt % added SP-B1–25 peptide at collapse
at 37°C. The isotherm is quite similar to that in Fig. 1 D.
The peptide partitions mainly into the fluid phase domains
and does not affect the solid phase domains to any great
extent. From these and earlier results (Lipp et al., 1998), the
folding transition is relatively independent of the details of
the lipid composition of the monolayer. There is also a
minimum fraction of SP-B required in the monolayer to
induce the monolayer folding transition. A minimum frac-
tion of SP-B is also necessary for optimal surfactant per-
formance in vivo. Adding native SP-B (Mizuno et al., 1995)
FIGURE 3 The speed of a magnetic needle floating on a surfactant-
covered interface at a given magnetic force was measured as a function of
surface pressure for DPPC/POPG (77:23, wt/wt) monolayers with differing
PA content on a pure water subphase at 25°C. The speed is normalized to
the needle velocity on a clean, surfactant-free interface. A high needle
velocity corresponds to a low monolayer viscosity, although it is difficult
to assign a single value to the viscosity of a non-Newtonian monolayer.
With no PA in the monolayer, the needle velocity is nearly independent of
surface pressure and is not significantly different from a clean interface
(normalized speed of 1). For a PA fraction of 10%, there is a transition
between 30 and 40 mN/m from high needle velocity to low needle velocity.
This change in the monolayer mechanical properties correlates with a
change in the morphological transitions in Fig. 2 and with the collapse
structures seen in Fig. 4. For 20 wt % PA, the monolayer is much stiffer,
and by 20 mN/m, we cannot drive the needle across the interface with the
maximum force we can apply. For surface pressures 
50 mN/m, the
needle often sinks and we cannot measure surface viscosity.
as shown on the height trace. The bright white specks across the image are small aggregates of Survanta dispersed in the aqueous phase that were trapped
during transfer. (E) AFM image of Survanta monolayer transferred at a surface pressure of 55 mN/m and 30°C, just above the plateau in the isotherm. The
solid phase is now dark gray and the fluid phase is lighter gray. As in B, the fluid phase domains have thickened, but here they are only 1–2 nm higher
than the solid phase domains. As the amount of thickening of the fluid domains scales with the amount of SP-C present, this may be consistent with a smaller
fraction of SP-C in Survanta than in the model films. Overall, the general features of Survanta films appear very similar to the DPPC/POPG/PA/SP-Cff
films shown in B.
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or SP-B1–25 peptide (Walther et al., 1997) to Survanta
improves oxygenation and other measures of surfactant
performance in animals. Antibodies to SP-B or a genetic
deficiency of SP-B causes respiratory failure (Robertson
and Halliday, 1998; Tokieda et al., 1997).
Correlating morphological and isotherm measurements of
Langmuir monolayers to the organization and mechanics of
the surfactant within the alveoli during normal breathing is
much more problematic. The maximum static surface ten-
sion within excised rabbit lungs was measured to be 30
mN/M (surface pressure of 40 mN/m) (Bachofen et al.,
1987), while the minimum surface tension has been esti-
mated to be close to zero (Bachofen et al., 1987; Schu¨rch et
al., 1976, 1978). No measurements have been done of the
dynamic surface tension during the normal respiratory cy-
cle, so the range of surface tensions during actual breathing
is unknown. The maximum surface tension (minimum sur-
face pressure) on a Langmuir trough depends on the mode
of deposition of surfactant and the concentration, if any, of
surfactant in the subphase, but can range from 40 (Schu¨rch
et al., 1976, 1978) to 70 mN/m (surface pressures of 30–0
mN/m). In our experiments, the surface pressure was forced
to cycle between zero and the collapse pressure of the
particular surfactant mixture by varying the surface area; it
is unclear if either the maximum or minimum surface pres-
sure shown in the isotherms are reached during breathing.
However, both of the prominent morphological transitions
we have observed—the multilayer formation induced by
SP-C in the fluid phase domains and the folding transition at
collapse induced by SP-B—occur at surface pressures be-
tween 40 and 70 mN/m on compression, which shows that
these are within the range of measured maximum and min-
imum surface tensions in static lungs.
The change in surface area of the lungs during breathing
is an important corollary to the range of surface tension
during breathing. When lung volume changes from 40 to
100% of total lung capacity, the lung epithelial cell basal
surface area increases 35% (Tschumperlin and Margulies,
1999). However, the actual area change of the air-fluid
interface is more difficult to measure (Wirtz and Dobbs,
2000). Secretion of surfactant from the type II cell is pos-
tulated to be induced by deep sighing breaths and the
resulting large increases in the lung volume and surface area
(Wirtz and Dobbs, 2000). The change in relative area in
Langmuir isotherms is arbitrary; the monolayer area is
changed sufficiently so that the entire range between the
collapse pressure and zero surface pressure is recorded. The
relative change in surface pressure for a given change in
FIGURE 4 (A) Fluorescence optical micrograph of coexisting mono-
layer and folded region in a film of DPPC/POPG/PA/SP-B1–78, in weight
ratio 68:22:8:3 at the collapse pressure of 65 mN/m at 37°C. The bright
fluid phase network (likely containing POPG, the protein and the fluores-
cent lipid, which separates into disordered phases) separates the darker
solid phase domains (probably containing the DPPC and PA) both in the
monolayer and in the folded region (Lipp et al., 1998). The organization
and distribution of the domains remains the same within the folds, implying
that the composition also remains the same. The folds reincorporate into
the monolayer on expansion over a range in surface pressure from the
collapse pressure to 15 mN/m. The folds always protrude into the
subphase. Without SP-B the films do not fold, but rather fracture, as in Fig.
4B. (B) Fluorescence image of Survanta at 37°C at collapse showing a
similar solid-fluid phase coexistence (see Fig. 4A), although with signifi-
cantly smaller domains. At collapse, Survanta fractures to form bright
cracks at the interface. The materials in and around the cracks are slow to
respread on expansion of the monolayer. (C) Fluorescence image of Sur-
vanta with 5 wt % added SP-B1–25 peptide at collapse at 37°C. As in Fig.
4B, there is solid-fluid phase coexistence with a small domain size, but the
added SP-B causes the monolayer to undergo a reversible folding as in the
model mixture (Fig. 4A). The folds are somewhat smaller than in the model
mixture and appear to scale with the domain size. The folded regions
appear to have the same overall composition as the rest of the monolayer,
and reincorporate readily into the monolayer on expansion.
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area is typically much greater on expansion than on com-
pression of the monolayer (see Fig. 1), especially at high
surface pressures after monolayer collapse. Hence, a given
change in area could result in a much larger change in
surface pressure depending on the history of the monolayer.
The folds in the collapsed monolayer (Fig. 4) or the multi-
layers in the fluid domains (Fig. 2) revert back to the
monolayer over a range of surface pressures from the col-
lapse pressure to as low as 15 mN/m. It is unclear if the
change in surface area during normal breathing would cause
these structures to occur or disappear on each breathing
cycle.
CONCLUSIONS
Although the clinical importance of the LS proteins SP-B
and SP-C is well established (Tanaka et al., 1986; Poulain
and Clements, 1995; Hawgood et al., 1998; Goerke, 1998;
Johansson, 1998), the role of these proteins in altering the
properties of surfactant monolayers remains ambiguous. It
is also relatively well established that the fatty acid and
unsaturated lipid components of lung surfactant are impor-
tant to the proper function of surfactant at all stages of the
compression and expansion cycle (Veldhuizen et al., 1998),
although the exact fraction of any lipid in lung surfactants is
still not well established. Direct imaging with fluorescence
and atomic force microscopy clearly show that the interac-
tions between SP-B, SP-C, and palmitic acid with the re-
maining lipid components of synthetic and animal extract
surfactants are non-ideal and lead to novel morphologies
likely to be important to LS function. Establishing the
properties of SP-B, SP-C, and PA are essential to determin-
ing the composition of an effective synthetic surfactant and
in evaluating synthetic peptide function.
SP-C retains a continuous fluid phase network of unsat-
urated lipids and proteins, separating islands of solid phase
lipids up to monolayer collapse. The nature of the fluid
phase transition depends on the lipid composition: when PA
is present in the monolayer, the fluid phase thickens uni-
formly, while without PA, the fluid phase forms multilayer
stacks. Native SP-C, palmitoylated, human recombinant
SP-C (von Nahmen et al., 1997), and SP-Cff appear to have
very similar effects on the monolayer.
With SP-B, collapse occurs by a reversible buckling in
which the monolayer is flexible enough to fold, while re-
taining sufficient cohesion to prevent loss of material to the
subphase. The folds have the same composition as the
monolayer, and reversibly reincorporate into the monolayer
on expansion. Both the full length protein, SP-B1–78, and
the SP-B1–25 peptide are capable of inducing this folding
transition.
PA, when added to DPPC monolayers, increases the
monolayer viscosity at high surface pressures, but not at low
surface pressure. This increased monolayer rigidity at high
surface pressures appears to be necessary to allow homo-
geneous multilayer formation in the fluid phase via SP-C
and the folding collapse mechanism in films also containing
SP-B. Higher fractions of PA likely make the monolayer too
rigid to respread.
These two- to three-dimensional transitions allow col-
lapse to occur at elevated surface pressures while making it
possible for the protein and unsaturated lipid components to
remain associated with the monolayer, facilitating rapid
respreading. Without the proteins, the fluid phase lipids are
squeezed-out from the monolayer, leaving behind a rigid
DPPC-rich monolayer that fractures irreversibly at collapse.
These morphological transitions of multilayer formation,
followed by a folding and unzipping process, explains how
lung surfactant can both achieve low surface tensions and
respread readily from the collapsed state, without the need
to undergo any compositional refinement upon compres-
sion. The presence of the protein-containing folds extending
into the subphase at high compression may also provide a
mechanism for incorporation of new material to the inter-
face upon expansion. A thorough understanding of the roles
of the lipids and proteins in lung surfactant can provide a
mechanism-based rationale for the design of replacement
surfactants for treatment of respiratory distress syndrome.
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